This report was first published by Endpoints News. To see the original version, click here
A Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing.
The startup, Windward Bio, has raised a collective $365 million from a who’s who of investors since January 2025. Its backers include OrbiMed, Novo Holdings, SR One, Omega Funds, RTW, Qiming Venture Partners, Quan Capital, RA Capital, Sanofi Ventures and Harbour BioMed, among others.
您已阅读25%（530字），剩余75%（1581字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。